Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies

Urology

Volumn 62, Issue 5, 2003, Pages 883-887

  Zigeuner, Richard ^a   Schips, Luigi ^a   Lipsky, Katja ^a   Auprich, Marko ^a   Salfellner, Michael ^a   Rehak, Peter ^a   Pummer, Karl ^a   Hubmer, Gerhart ^a  

^a UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SURGERY; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; FISHER EXACT TEST; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; TRANSURETHRAL RESECTION; URINARY TRACT OBSTRUCTION;

EID: 0242580191     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00663-0     Document Type: Article

References (22)

1. Stephenson R.A. Prostate cancer trends in the era of prostate specific antigen an update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am. 29:2002;173-181.
2. Quinn M., Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I international comparisons. BJU Int. 90:2002;162-173.
3. Horninger W., Reissigl A., Rogatsch H., et al. Prostate cancer screening in the Tyrol, Austria experience and results. Eur J Cancer. 36:2000;1322-1335.
4. Recker F., Kwiatkowski M.K., Huber A., et al. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng/ml combined with free-to-total ratio 20% or less the Aarau experience. J Urol. 166:2001;851-855.
5. Babaian R.J., Fritsche H., Ayala A., et al. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4 ng/ml. Urology. 56:2000;1000-1006.
6. Djavan B., Zlotta A., Kratzik C., et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/ml. Urology. 54:1999;517-522.
7. Roehrborn C.G., Boyle P., Gould A.L., et al. Serum prostate specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 53:1999;581-589.
8. Djavan B., Mazal P., Zlotta A., et al. Pathological features of prostate cancer detected on initial and repeat prostate biopsy results of the prospective European Prostate Cancer Detection study. Prostate. 47:2001;111-117.
9. Roehl K.A., Antenor J.V., Catalona W.J. Serial biopsy results in prostate cancer screening study. J Urol. 167:2002;2435-2439.
10. Kitamura H., Masumori N., Tanuma Y., et al. Does transurethral resection of the prostate facilitate detection of clinically significant prostate cancer that is missed with systemic sextant and transition zone biopsies? Int J Urol. 9:2002;95-99.
11. Rovner ES, Schanne FJ, Malkowicz SB, et al. Transurethral biopsy of the prostate for persistently elevated or increasing prostate specific antigen following multiple negative transrectal biopsies. J Urol 158: 138-141, 1997.
12. Pacelli A., Bostwick D.G. Clinical significance of high grade prostatic intraepithelial neoplasia in transurethral resection specimens. Urology. 50:1997;355-359.
13. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate specific antigen in a community-based population of healthy men establishment of age-specific reference ranges. JAMA. 270:1993;860-864.
14. De Antoni E.P., Crawford E.D., Oesterling J.E., et al. Age- and race-specific reference ranges for prostate specific antigen from a large community-based study. Urology. 48:1996;234-239.
15. Onder A.U., Yalcin V., Arar O., et al. Impact of transition zone biopsies in detection and evaluation of prostate cancer. Eur Urol. 33:1998;542-548.
16. Bazinet M., Karakiewicz J., Goyal M., et al. Value of systematic transition zone biopsies in the early detection of prostate cancer. J Urol. 155:1996;605-606.
17. Reissigl A., Pointner J., Strasser H., et al. Frequency and clinical significance of transition zone cancer in prostate cancer screening. Prostate. 30:1997;130-135.
18. Keetch D.W., Catalona W.J. Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values. J Urol. 154:1995;1795-1797.
19. Ornstein D.K., Rao G.S., Smith D.S., et al. The impact of systemic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. J Urol. 157:1997;880-883.
20. Vanasupa B.P., Miller T.A., Schwartz B.F. Diagnosis of prostate adenocarcinoma using transurethral resection of the prostate after multiple negative transrectal biopsies and persistently elevated prostate-specific antigen level. Urology. 56:2000;1056.
21. Niesel T., Breul J., Hartung R. Diagnostic value of additional systematic prostate biopsies in patients undergoing transurethral resection of the prostate. Urology. 49:1997;869-873.
22. O'Dowd G.J., Miller M.C., Orozco R., et al. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology. 55:2000;553-559.